Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

Clinical trial NCT03691077 · UNKNOWN

Trial details

NCT number: NCT03691077
Sponsor: Assistance Publique - Hôpitaux de Paris
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis Relapse Primary Progressive Multiple Sclerosis

Start date: 2018-11-11
Primary completion: 2024-05-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.